, GlobeNewswire
Addex Pharmaceuticals Announces Board Changes
Addex Pharmaceuticals /
Addex Pharmaceuticals Announces Board Changes
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Vincent Lawton appointed to Vice-Chairman
Geneva, Switzerland, 11 August 2011 - Addex Pharmaceuticals (SIX:ADXN), a leader
in allosteric modulation-based drug discovery and development, announced today
changes to the Company's Board of Directors. Vincent Lawton, an existing
director at Addex, has been appointed Vice-Chairman. In addition, Vincent Mutel
formally resigned his position as Member of the Board of Directors of Addex. As
previously announced, Dr. Mutel stepped down from his position as CEO of Addex
on June 3, 2011.
Mr. Lawton, who was previously Managing Director of Merck Sharp & Dohme (MSD)
U.K. and Vice President of MSD Europe, both subsidiaries of Merck & Co., Inc.,
has served on the Addex Board since April 2009.
"We are pleased to acknowledge the important role Vincent Lawton played during
the past two years, including his recent role as interim Managing Director
during this transition period while we are recruiting a new CEO," said André
Mueller, executive chairman of Addex. "The board congratulates Mr. Lawton and we
all look forward to his continued leadership as we build shareholder value for
Addex."
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops small
molecule drugs based on allosteric modulation that have the potential to be
highly specific and significantly safer than traditional small molecule drugs.
The company uses its proprietary small molecule discovery platform to
specifically target cell surface receptors that are recognized as having
therapeutic potential for treating important neurological, metabolic or
inflammatory diseases. Separate Phase IIa clinical trials are ongoing for
dipraglurant (ADX48621) to treat PD-LID and ADX71149 to treat schizophrenia in
collaboration with Janssen Pharmaceuticals, Inc. In addition, Merck & Co., Inc.
has licensed rights to preclinical mGluR4 PAM for Parkinson's disease. In
addition, the company has several preclinical programs including: mGluR2 NAM for
treating Alzheimer's disease; GLP-1R PAM and related receptors for treating
metabolic disorders; TrkB PAM for treating neurodegenerative diseases (e.g.
Alzheimer's, Parkinson's and Huntington's diseases) and other members in the
receptor tyrosine kinase superfamily; TNFR1 for treating inflammatory conditions
and other members of the TNF receptor superfamily; IL1R1 NAM for treating gout
and type II diabetes as well as other members of the interleukin receptor
family; follicle stimulating hormone receptor (FSHR) NAM for treatment of
endometriosis and benign prostatic hyperplasia; and GABA-BR PAM for treatment of
chronic pain, Fragile X syndrome, urinary incontinence and gastroesophageal
reflux disease.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1537733]
Addex Pharmaceuticals Announces Board Changes
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Vincent Lawton appointed to Vice-Chairman
Geneva, Switzerland, 11 August 2011 - Addex Pharmaceuticals (SIX:ADXN), a leader
in allosteric modulation-based drug discovery and development, announced today
changes to the Company's Board of Directors. Vincent Lawton, an existing
director at Addex, has been appointed Vice-Chairman. In addition, Vincent Mutel
formally resigned his position as Member of the Board of Directors of Addex. As
previously announced, Dr. Mutel stepped down from his position as CEO of Addex
on June 3, 2011.
Mr. Lawton, who was previously Managing Director of Merck Sharp & Dohme (MSD)
U.K. and Vice President of MSD Europe, both subsidiaries of Merck & Co., Inc.,
has served on the Addex Board since April 2009.
"We are pleased to acknowledge the important role Vincent Lawton played during
the past two years, including his recent role as interim Managing Director
during this transition period while we are recruiting a new CEO," said André
Mueller, executive chairman of Addex. "The board congratulates Mr. Lawton and we
all look forward to his continued leadership as we build shareholder value for
Addex."
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops small
molecule drugs based on allosteric modulation that have the potential to be
highly specific and significantly safer than traditional small molecule drugs.
The company uses its proprietary small molecule discovery platform to
specifically target cell surface receptors that are recognized as having
therapeutic potential for treating important neurological, metabolic or
inflammatory diseases. Separate Phase IIa clinical trials are ongoing for
dipraglurant (ADX48621) to treat PD-LID and ADX71149 to treat schizophrenia in
collaboration with Janssen Pharmaceuticals, Inc. In addition, Merck & Co., Inc.
has licensed rights to preclinical mGluR4 PAM for Parkinson's disease. In
addition, the company has several preclinical programs including: mGluR2 NAM for
treating Alzheimer's disease; GLP-1R PAM and related receptors for treating
metabolic disorders; TrkB PAM for treating neurodegenerative diseases (e.g.
Alzheimer's, Parkinson's and Huntington's diseases) and other members in the
receptor tyrosine kinase superfamily; TNFR1 for treating inflammatory conditions
and other members of the TNF receptor superfamily; IL1R1 NAM for treating gout
and type II diabetes as well as other members of the interleukin receptor
family; follicle stimulating hormone receptor (FSHR) NAM for treatment of
endometriosis and benign prostatic hyperplasia; and GABA-BR PAM for treatment of
chronic pain, Fragile X syndrome, urinary incontinence and gastroesophageal
reflux disease.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1537733]
Relevante Links: Addex Therapeutics Ltd